Aquablation: How I Do It
Dr. Brian Helfand outlines a reproducible approach to Aquablation for consistent BPH surgical outcomes.
Read More
Select Page
Brian T. Helfand, MD, PhD, is Chief of the Division of Urology and an Associate Chief Scientific Officer at NorthShore University HealthSystem in Evanston, Illinois. Dr. Helfand also serves as a Clinical Professor at the University of Chicago. He specializes in urologic oncology and the treatment of prostate conditions. Dr. Helfand’s clinical expertise includes minimally invasive surgery, advanced laparoscopy, and procedures using the da Vinci robotic system.
Dr. Helfand earned his Bachelor’s of Science in Neuroscience and Behavioral Biology, medical degree, and PhD in Cell and Molecular Biology and Genetics from Northwestern University in Chicago, Illinois. He then completed an internship in General Surgery, residency in Urology, and fellowship in Urologic Oncology at Northwestern University.
Dr. Helfand is an internationally-known urologist and genomic translational researcher. He has received multiple grants from the National Institutes of Health and has published over 140 peer-reviewed manuscripts in journals such as Nature Genetics, The Journal of Cell Biology, and Science Translational Medicine. Dr. Helfand is also involved in national and international research collaborations as an active member of the International Consortium for Prostate Cancer Genetics, the Prostate Cancer Specialized Program of Research Excellence, the IMPACT study, and the Lower Urinary Tract Dysfunction Research Network. His current research goals are focused on germline genetic variations and mutations in order to assist in personal and informed clinical decision making about prostate cancer screening and treatment for patients and their family members.
Brian T. Helfand, MD, PhD | Mar 2026
Dr. Brian Helfand outlines a reproducible approach to Aquablation for consistent BPH surgical outcomes.
Read MoreBrian T. Helfand, MD, PhD | Mar 2026
Dr. Brian Helfand describes prostate cancer aquablation as a subtotal resection technique that preserves function while reducing cancer progression risk.
Read MoreBrian T. Helfand, MD, PhD | Feb 2026
A head-to-head comparison of two PSMA PET radiotracers in post-prostatectomy biochemical recurrence.
Read MoreBrian T. Helfand, MD, PhD | Nov 2025
Dr. Brian T. Helfand reviews germline mutations and polygenic risk scores that shape prostate cancer risk, aggressiveness, and treatment decisions.
Read MoreBrian T. Helfand, MD, PhD | Nov 2025
Brian T. Helfand, MD, PhD, discusses focal therapy in prostate cancer management, emphasizing its potential and challenges.
Read More